Bibliography
- Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002;359(9317):1541-9
- Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353(23):2462-76
- Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003;98(6):1315-24
- Breynaert C, Ferrante M, Fidder H, et al. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study. Am J Gastroenterol 2011;106(4):778-85
- Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohns Colitis 2008;2(3):219-25
- Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58(4):501-8
- Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 2009;29(3):286-97
- Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58(4):492-500
- Ducharme J, Pelletier C, Zacharias R. The safety of infliximab infusions in the community setting. Can J Gastroenterol 2010;24(5):307-11
- Zabana Y, Domènech E, Mañosa M, et al. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther 2010;31(5):553-60
- Lee TW, Singh R, Fedorak RN. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study. Aliment Pharmacol Ther 2011;34(2):181-7
- Buch MH, Bryer D, Lindsay S, et al. Shortening infusion times for infliximab administration. Rheumatology (Oxford) 2006;45(4):485-6
- Clare DF, Alexander FC, Mike S, et al. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2009;21(1):71-5
- European Organisation for Research and Treatment of Cancer. Common Toxicity Criteria Version 2.0. 1999. Available from: http://www.eortc.be/services/doc/ctc/ctcv20_4-30-992.pdf [Accessed 14 January 2012]
- Bhat S, Sharma D, Doherty P, et al. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease? Inflamm Bowel Dis 2010;16(11):1922-5
- Colombel JF, Sandborn WJ, Reinisch W, et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362(15):1383-95